Article Figures & Data
Figures
- Fig 1.
A–C, A 48-year-old woman with glioblastoma with a methylated MGMT promoter gene has a remote tumor mass on the contrast-enhanced T1-weighted image (A) immediately after the concomitant chemoradiotherapy. MR perfusion image (B) reflects a slight increase of CBV, indicating an rCBV of 1.41 compared with contralateral white matter. After 4 months' continuation of TMZ, enhancement of the lesion decreases without further treatment, which is compatible with pseudoprogression (C). D–F, A 65-year-old man with glioblastoma with unmethylated MGMT has a progressive enhancing lesion involving on the splenium (D). MR perfusion image (E) demonstrates a high increase of CBV indicating an rCBV of 4.38. After 2 months, the lesion shows stronger enhancement and more enlargements, demonstrating real tumor progression (F).
- Fig 2.
OS by the presence of the MGMT promoter methylation status (A) and by the presence of pseudoprogression or early tumor progression (B).
- Fig 3.
Diagram of the study design.
- Fig 4.
ROC curve of rCBV predicting pseudoprogression. The rCBV ratio of >1.49 has an 81.5% sensitivity and 77.8% specificity.
Tables
- Table 1:
Characteristics at baseline of 90 patients with newly diagnosed glioblastoma treated with concurrent chemoradiotherapy
Characteristics No. Median age (yr) (range) 50 (25–74) Male/female ratio 49/41 WHO performance score 0–1 vs 2 79/11 Complete or partial resection vs biopsy 90/0 MGMT promoter status methylated/unmethylated 40/33 No. rCBV 95% CI P Value Unmethylated group 22 .009 Pseudoprogression 4 0.87 0.10–1.63 Real progression 12 3.25 1.46–5.04 Methylated group 26 .258 Pseudoprogression 9 1.56 0.57–2.55 Real progression 7 2.34 1.05–3.61
In this issue
Jump to section
Related Articles
Cited By...
- Advanced Distance-Resolved Evaluation of the Perienhancing Tumor Areas with FLAIR Hyperintensity Indicates Different ADC Profiles by MGMT Promoter Methylation Status in Glioblastoma
- Application of 7T MRS to High-Grade Gliomas
- Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
- MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features
- Vessel Type Determined by Vessel Architectural Imaging Improves Differentiation between Early Tumor Progression and Pseudoprogression in Glioblastoma
- Radiogenomics-based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance
- Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors
- Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project
- Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI
- MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status
- ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain
- Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
- Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis
- Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study